U.S. Surpasses Europe As First-Launch Locale, Top Drug Innovator – Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The U.S. overtook Europe as the leading market for initial launch of novel therapeutics during the period from 1993 to 2003, according to a study published in the March/April issue of Health Affairs.
You may also be interested in...
FDA’s 2005 New Molecular Entity Total: 18, Including Five In December
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product